Progen Pharmaceuticals (www.progen. com.au) will use Quintiles’ (www.quintiles.com) services for clinical development-related projects. This agreement includes the execution of the Phase III trial of anticancer drug PI-88 for the treatment of primary liver cancer (hepatocellular carcinoma). Progen says that it is on track to initiate recruitment in the fourth quarter of 2007.
